Human Gene Therapy - April 2023 - 288

288
WESTHAUS ET AL.
ture, and Function. Methods in Molecular Biology
(Turksen K, ed.) Humana Press: New York, NY,
USA; 2019; Vol. 1576; pp. 123-133.
42. Wei J, Ran G, Wang X, et al. Gene manipulation
in liver ductal organoids by optimized recombinant
adeno-associated virus vectors. J Biol Chem 2019;
294(38):14096-14104.
43. Cabanes-Creus M, Hallwirth CV, Westhaus A,
et al. Restoring the natural tropism of AAV2
vectors for human liver. Sci Transl Med 2020;
12(560):eaba3312.
44. Cabanes-Creus M, Navarro RG, Liao SHY, et al.
Single amino acid insertion allows functional
transduction of murine hepatocytes with human
liver tropic AAV capsids. Mol Ther Methods Clin
Dev 2021;21:607-620.
45. Cabanes-Creus M, Ginn SL, Amaya AK, et al.
Codon-optimization of wild-type adeno-associated
virus capsid sequences enhances DNA family
shuffling while conserving functionality. Mol Ther
Methods Clin Dev 2019;12:71-84.
46. Perocheau DP, Cunningham S, Lee J, et al. Agerelated
seroprevalence of antibodies against AAVLK03
in a UK Population Cohort. Hum Gene Ther
2018;30(1):79-87.
47. Salas D, Kwikkers KL, Zabaleta N, et al. Immunoadsorption
enables successful rAAV5mediated
repeated hepatic gene delivery in
nonhuman primates. Blood Adv 2019;3(17):2632-
2641.
48. Nakabayashi H, Taketa K, Miyano K, et al. Growth
of human hepatoma cell lines with differentiated
functions in chemically defined medium. Cancer
Res 1982;42(9):3858.
49. Lo´pez-Terrada D, Cheung SW, Finegold MJ, et al.
Hep G2 is a hepatoblastoma-derived cell line.
Hum Pathol 2009;40(10):1512-1515.
50. Prior N, Inacio P, Huch M. Liver organoids: From
basic research to therapeutic applications. Gut
2019;68(12):2228.
51. Belfiore L, Aghaei B, Law AMK, et al. Generation
and analysis of 3D cell culture models for
drug discovery. Eur J Pharm Sci 2021;163:
105876.
52. Xiong T, Li J, Chen F, et al. PCAT-1: A novel
oncogenic long non-coding RNA in human cancers.
Int J Biol Sci 2019;15(4):847-856.
53. Yang Z, Zhao S, Zhou X, et al. PCAT-1: A pivotal
oncogenic long non-coding RNA in human cancers.
Biomed Pharmacother 2019;110:493-499.
54. Paine-Saunders S, Viviano BL, Saunders S. GPC6,
a novel member of the glypican gene family, encodes
a product structurally related to GPC4 and
is colocalized with GPC5 on human chromosome
13. Genomics 1999;57(3):455-458.
55. Wang L, Bell P, Somanathan S, et al. Comparative
study of liver gene transfer with AAV vectors
based on natural and engineered AAV capsids.
Mol Ther 2015;23(12):1877-1887.
56. Monaci P, Nicosia A, Cortese R, et al. Two different
liver-specific factors stimulate in vitro
transcription from the human alpha 1-antitrypsin
promoter. EMBO J 1988;7(7):2075-2087.
57. Simonet WS, Bucay N, Lauer SJ, et al. A fardownstream
hepatocyte-specific control region
directs expression of the linked human apolipoprotein
E and C-I genes in transgenic mice. J Biol
Chem 1993;268(11):8221-8229.
58. Thomas CE, Storm TA, Huang Z, et al. Rapid uncoating
of vector genomes is the key to efficient
liver transduction with pseudotyped adenoassociated
virus vectors. J Virol 2004;78(6):3110.
59. Wang L, Calcedo R, Wang H, et al. The pleiotropic
effects of natural AAV infections on liver-directed
gene transfer in macaques. Mol Ther 2010;18(1):
126-134.
60. Wang L, Calcedo R, Bell P. Impact of pre-existing
immunity on gene transfer to nonhuman primate
liver with adeno-associated virus 8 vectors. Hum
Gene Ther 2011;22(11):1389-1401.
61. Wang M, Sun J, Crosby A, et al. Direct interaction
of human serum proteins with AAV virions to
enhance AAV transduction: Immediate impact on
clinical applications. Gene Ther 2017;24(1):49-59.
62. Weber T. Anti-AAV antibodies in AAV gene
therapy: Current challenges and possible solutions.
Front Immunol 2021;12:658399.
63. Calcedo R, Morizono H, Wang L, et al. Adenoassociated
virus antibody profiles in newborns,
children, and adolescents. Clin Vaccine Immunol
2011;18(9):1586-1588.
64. Li C, Narkbunnam N, Samulski RJ, et al. Neutralizing
antibodies against adeno-associated virus
examined prospectively in pediatric patients
with hemophilia. Gene Ther 2012;19(3):288-294.
65. Baruteau J, Waddington SN, Alexander IE, et al.
Gene therapy for monogenic liver diseases: Clinical
successes, current challenges and future prospects.
J Inherit Metab Dis 2017;40(4):497-517.
66. Boutin S, Monteilhet V, Veron P, et al. Prevalence of
serum IgG and neutralizing factors against adenoassociated
virus(AAV) types1,2,5,6,8,and 9
in the healthy population: Implications for gene
therapy using AAV vectors. Hum Gene Ther
2010;21(6):704-712.
67. Ling C, Wang Y, Feng YL, et al. Prevalence of
neutralizing antibodies against liver-tropic adenoassociated
virus serotype vectors in 100 healthy
Chinese and its potential relation to body constitutions.
J Integr Med 2015;13(5):341-346.
68. Louis Jeune V, Joergensen JA, Hajjar RJ, et al.
Pre-existing anti-adeno-associated virus antibodies
as a challenge in AAV gene therapy. Hum
Gene Ther Methods 2013;24(2):59-67.
69. Meliani A, Leborgne C, Triffault S, et al. Determination
of anti-adeno-associated virus vector neutralizing
antibody titer with an In Vitro Reporter
System. Hum Gene Ther Methods 2015;26(2):45-
53.
70. Bertin B, Veron P, Leborgne C, et al. Capsidspecific
removal of circulating antibodies to adenoassociated
virus vectors. Sci Rep 2020;10(1):864.
71. Orlowski A, Katz MG, Gubara SM, et al. Successful
transduction with AAV Vectors after
selective depletion of anti-AAV antibodies by
immunoadsorption. Mol Ther Methods Clin Dev
2020;16:192-203.
72. Elmore ZC, Oh DK, Simon KE, et al. Rescuing AAV
gene transfer from neutralizing antibodies with an
IgG-degrading enzyme. JCI Insight 2020;5(19):
e139881.
73. Leborgne C, Barbon E, Alexander JM, et al. IgGcleaving
endopeptidase enables in vivo gene
therapy in the presence of anti-AAV neutralizing
antibodies. Nat Med 2020;26(7):1096-1101.
74. Hatit MZC, Lokugamage MP, Dobrowolski CN,
et al. Species-dependent in vivo mRNA delivery
and cellular responses to nanoparticles. Nat Nanotechnol
2022;17(3):310-318.
Received for publication October 1, 2022;
accepted after revision February 19, 2023.
Published online: March 16, 2023.
Human Gene Therapy - April 2023

Table of Contents for the Digital Edition of Human Gene Therapy - April 2023
